Kolistimetatnatrium Noridem (Colistimethate Sodium)

Colistimethate sodium is a prodrug that converts to colistin in the body. Colistin binds to the lipopolysaccharide component of Gram‑negative bacterial outer membranes, disrupting membrane integrity, increasing permeability, and causing bacterial cell death.

The dose of Kolistimetatnatrium Noridem is determined by the prescribing clinician based on the infection type, severity, patient weight, renal function, and route of administration. Exact dosing regimens are individualized and should follow local clinical guidelines.

Safety of colistimethate sodium in pregnancy and lactation has not been definitively established. Use during pregnancy or while breastfeeding should only occur if the potential benefit justifies the potential risk to the fetus or infant, and after careful clinical assessment.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required), and necessary import documentation.

Kolistimetatnatrium Noridem delivers colistimethate sodium via intracerebroventricular or intrathecal routes, providing higher local concentrations in the central nervous system compared with systemic polymyxin formulations. This targeted delivery can improve efficacy against CNS infections while potentially reducing systemic toxicity.

The product should be stored at 2‑8 °C, kept refrigerated, protected from light, and not frozen. It must be handled in a sterile environment, and any reconstituted solution should be used promptly according to aseptic technique.

Kolistimetatnatrium Noridem is administered by a trained healthcare professional directly into the cerebrospinal fluid via intracerebroventricular or intrathecal injection, allowing the drug to reach therapeutic concentrations at the site of infection.

Serious risks include nephrotoxicity, neurotoxicity, ototoxicity, severe neuromuscular blockade leading to respiratory failure, and rare anaphylactic reactions. Patients should be closely monitored for renal function, neurological status, and signs of allergic response throughout therapy.

Patients with known hypersensitivity to colistimethate sodium or any component of the formulation should avoid use. Additionally, individuals with severe renal impairment, uncontrolled neuromuscular disorders, or those receiving concurrent neuromuscular blocking agents should not be given this medication without specialist supervision.